ATE404574T1 - Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden - Google Patents

Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Info

Publication number
ATE404574T1
ATE404574T1 AT04809566T AT04809566T ATE404574T1 AT E404574 T1 ATE404574 T1 AT E404574T1 AT 04809566 T AT04809566 T AT 04809566T AT 04809566 T AT04809566 T AT 04809566T AT E404574 T1 ATE404574 T1 AT E404574T1
Authority
AT
Austria
Prior art keywords
proliferation
inhibiting
platinum complexes
tumor cells
complexes
Prior art date
Application number
AT04809566T
Other languages
English (en)
Inventor
James Turkson
Richard Jove
Jay Palmer
Heidi Kay
Hua Yu
Original Assignee
Univ South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida filed Critical Univ South Florida
Application granted granted Critical
Publication of ATE404574T1 publication Critical patent/ATE404574T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/04—Amoebicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04809566T 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden ATE404574T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US48122603P 2003-08-13 2003-08-13
US51558003P 2003-10-30 2003-10-30
US51994303P 2003-11-14 2003-11-14
US52529503P 2003-11-25 2003-11-25

Publications (1)

Publication Number Publication Date
ATE404574T1 true ATE404574T1 (de) 2008-08-15

Family

ID=34199238

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04781131T ATE453653T1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren
AT04809566T ATE404574T1 (de) 2003-08-13 2004-08-13 Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04781131T ATE453653T1 (de) 2003-08-13 2004-08-13 Platinkomplexe zur behandlung von tumoren

Country Status (8)

Country Link
US (6) US7566798B2 (de)
EP (2) EP1675864B1 (de)
JP (2) JP2007502777A (de)
AT (2) ATE453653T1 (de)
AU (3) AU2004264421B2 (de)
CA (2) CA2535584A1 (de)
DE (2) DE602004024909D1 (de)
WO (2) WO2005016946A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2535584A1 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050288365A1 (en) * 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
CA2563305A1 (en) * 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
US7977500B2 (en) * 2004-11-10 2011-07-12 University Of South Florida Platinum complexes for targeted drug delivery
US7951374B2 (en) * 2004-12-14 2011-05-31 University Of South Florida Methods for inhibiting STAT3 signaling in immune cells
DE102004060934A1 (de) * 2004-12-17 2006-06-29 Wacker Chemie Ag Vernetzbare Polyorganosiloxanmassen
DE602006018299D1 (de) * 2005-06-30 2010-12-30 Bionumerik Pharmaceuticals Inc Platinanaloga mit monoazolligand
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
US20100247427A1 (en) * 2005-10-14 2010-09-30 University Of South Florida Methods of inhibiting cell growth and methods of enhancing radiation responses
DE102006040647A1 (de) * 2006-08-30 2008-03-13 Robert Bosch Gmbh Handwerkzeugmaschine
WO2008144616A1 (en) 2007-05-18 2008-11-27 Heidi Kay Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
US8895610B1 (en) 2007-05-18 2014-11-25 Heldi Kay Platinum (IV) compounds targeting zinc finger domains
CA2691047A1 (en) * 2007-06-18 2008-12-24 Platco Technologies (Proprietary) Limited Platinum (iv) complexes
EP3050566B1 (de) * 2007-09-10 2018-11-28 Boston Biomedical, Inc. Neue gruppe von stat3-pfad-hemmern und krebs-stammzell-pfad-hemmer
WO2010067335A1 (en) 2008-12-12 2010-06-17 Platco Technologies (Proprietary) Limited Platinum (iv) complexes for use in the treatment of proliferative diseases such as cancer
DK3327148T3 (da) 2010-06-18 2021-04-12 Myriad Genetics Inc Fremgangsmåder til forudsigelse af status for brca1- og brca2-gener i en cancercelle
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
EP4563709A3 (de) 2011-06-17 2025-09-03 Myriad Genetics, Inc. Methoden und materialien zur beurteilung des allelischen ungleichgewichts
RU2491936C2 (ru) * 2011-07-11 2013-09-10 Борис Николаевич Анисимов Способ комплексного лечения больных паразитарными заболеваниями
CN107267598B (zh) 2011-12-21 2022-03-25 美瑞德生物工程公司 用于评估杂合性丢失的方法与材料
WO2013130347A1 (en) 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
ES2658867T3 (es) 2012-06-07 2018-03-12 Institut Curie Métodos para detectar la inactivación de la ruta de recombinación homóloga (BRCA1/2) en tumores humanos
WO2014160080A1 (en) 2013-03-14 2014-10-02 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
CA2907356C (en) 2013-03-15 2022-07-12 Sherri Ann MCFARLAND Metal-based coordination complexes as photodynamic compounds and their use
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
CN104230997B (zh) * 2013-06-13 2017-01-04 上海医药工业研究院 一种铂（ⅱ）配合物、其制备方法、药物组合物及应用
US20160185808A1 (en) * 2013-07-25 2016-06-30 Srinivas Ganta Platinum derivatives for hydrophobic formulations
EP3080292B1 (de) 2013-12-09 2022-02-02 Institut Curie Verfahren zum nachweis der inaktivierung des homologen rekombinationssignalwegs (brca1/2) bei menschlichen tumoren
EP4234711B1 (de) 2014-08-15 2025-05-28 Myriad Genetics, Inc. Verfahren und materialien zur beurteilung eines mangels an homologer rekombination
KR20180018800A (ko) 2015-06-19 2018-02-21 신-낫 프로덕츠 엔터프라이즈 엘엘씨 카보플라틴 계 공-결정의 약제학적 조성물 및 이의 용도
BR112017027277A2 (pt) 2015-06-19 2018-09-04 Syn Nat Products Entpr Llc ?método para o tratamento ou prevenção de uma doença e métodos para matar uma célula?
CA2989001A1 (en) 2015-06-25 2016-12-29 Syn-Nat Products Enterprise LLC Pharmaceutical co-crystal composition and use thereof
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
JP7356438B2 (ja) 2017-11-21 2023-10-04 メドンケアー ファーマスーティカル カンパニー リミテッド ジシクロプラチンを含有する組み合わせ製剤、その調製及びその使用
CN112175014B (zh) * 2020-10-10 2021-08-20 中国药科大学 一种一氧化氮供体型四价铂衍生物、制备方法及其医药用途
EP4141127B1 (de) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen
WO2024063828A1 (en) 2022-09-21 2024-03-28 Oracle International Corporation Expert-optimal correlation: contamination factor identification for unsupervised anomaly detection

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177263A (en) * 1972-02-28 1979-12-04 Research Corporation Anti-animal tumor method
GB1432563A (en) * 1972-04-10 1976-04-22 Rustenburg Platinum Mines Ltd Platinum- co-ordination compounds
GR851932B (de) * 1984-08-14 1985-12-13 Engelhard Corp
JPS6296A (ja) * 1985-03-06 1987-01-06 Sumitomo Pharmaceut Co Ltd 脂溶性白金（２）錯体
JPH01156989A (ja) * 1987-09-25 1989-06-20 Ss Pharmaceut Co Ltd 新規白金錯体
EP0328274B1 (de) * 1988-02-02 1994-10-19 Johnson Matthey, Inc., Pt(IV) Komplexe
JP3520367B2 (ja) * 1994-12-22 2004-04-19 独立行政法人産業技術総合研究所 白金ニトロアンミン系錯体の製造方法
AU4842996A (en) * 1995-02-28 1996-09-18 Yoshinori Kidani Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US5849790A (en) * 1995-11-17 1998-12-15 The University Of South Florida (Mono) ethylenediaminenitroplatinum (IV) complexes with ligands of oxides of nitrogen as possible anti-tumor agents
US6145688A (en) * 1996-07-17 2000-11-14 Smith; James C. Closure device for containers
US5977393A (en) 1997-11-21 1999-11-02 California Institute Of Technology Schiff base derivatives of ruthenium and osmium olefin metathesis catalysts
KR100246722B1 (ko) * 1997-12-30 2000-04-01 박호군 경구용 백금 착화합물 항암제 및 그 제조방법
EP1133317A1 (de) * 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
JP2003525862A (ja) * 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
US6960648B2 (en) * 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US7638122B2 (en) * 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
WO2005002508A2 (en) 2003-06-11 2005-01-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
CA2535584A1 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050288365A1 (en) 2004-01-06 2005-12-29 Heidi Kay Platinum complexes and methods for inhibiting tumor cell proliferation
US7977500B2 (en) 2004-11-10 2011-07-12 University Of South Florida Platinum complexes for targeted drug delivery
WO2007006019A1 (en) 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression

Also Published As

Publication number Publication date
US7238372B2 (en) 2007-07-03
US7566798B2 (en) 2009-07-28
US8247445B2 (en) 2012-08-21
JP2007502301A (ja) 2007-02-08
EP1664070B1 (de) 2008-08-13
US8598230B2 (en) 2013-12-03
EP1675864B1 (de) 2009-12-30
WO2005016946A2 (en) 2005-02-24
US20100310645A1 (en) 2010-12-09
CA2535584A1 (en) 2005-02-24
US20050080131A1 (en) 2005-04-14
WO2005023824A3 (en) 2005-06-09
DE602004015811D1 (de) 2008-09-25
AU2004264421B2 (en) 2011-02-24
AU2011202386A1 (en) 2011-06-09
AU2004264421A1 (en) 2005-02-24
WO2005016946A3 (en) 2005-09-29
US7763585B2 (en) 2010-07-27
WO2005023824A2 (en) 2005-03-17
US20100316704A1 (en) 2010-12-16
US20080187992A1 (en) 2008-08-07
EP1675864A2 (de) 2006-07-05
US7759510B2 (en) 2010-07-20
US20090285884A1 (en) 2009-11-19
ATE453653T1 (de) 2010-01-15
CA2535762A1 (en) 2005-03-17
AU2004270655B2 (en) 2011-03-24
JP2007502777A (ja) 2007-02-15
AU2004270655A1 (en) 2005-03-17
US20050074502A1 (en) 2005-04-07
EP1664070A2 (de) 2006-06-07
DE602004024909D1 (de) 2010-02-11

Similar Documents

Publication Publication Date Title
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE447965T1 (de) Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren
DE602006014843D1 (de) Verwendung von hif 1alfa modulatoren zur behandlung von krebs
EA200601554A1 (ru) Замещенные индол-о-глюкозиды
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
EA200602100A1 (ru) Соединения и способы для ингибирования митотической прогрессии
ATE554087T1 (de) Neue kinaseinhibitoren
DE602005021684D1 (de) Verfahren zur herstellung von pimecrolimus
DE69914085D1 (de) Verwendung von aryl- (oder heteroaryl-) azoylcarbinolderivaten zur behandlung von durch überschuss von substanz p hervorgerufenen beschwerden
DK1866433T3 (da) Fremgangsmåde til identifikation af LRRK-2interagerende molekyler og til rensning af LRRK2
WO2006034113A3 (en) Quinolone analogs as cell proliferation inhibitors
WO2003084475A3 (en) INHIBITORS OF THE S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF INHIBITING CANCER EMPLOYING THE SAME
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
DK1773420T3 (da) Anvendelse af gingivale fibroblaster til vaskulær celleterapi
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
TW200716132A (en) Novel chemical compounds
MXPA05001690A (es) Estrategia de deteccion para farmacos anticancer.
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
WO2005086909A3 (en) Protein kinase c iota
WO2005070042A3 (en) Novel chemical compounds
WO2006091965A3 (en) Nod1 as an anti-tumor agent
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
DE602005015329D1 (de) Rutheniumkomplexe zur krebsbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties